Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma (2021) Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel ME, et al. Journal article Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451 (2021) Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, et al. Journal article, Erratum Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours (2021) Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW, Pavel ME Journal article Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results (2021) Pavel ME, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, et al. Journal article Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST (2021) Srirajaskanthan R, Pavel ME, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO Journal article Treatment strategy by radioiodine refractory differentiated thyroid cancer (2021) Mantsopoulos K, Müller SK, Pavel ME, Kuwert T, Meidenbauer N, Fietkau R, Sievert M, Iro H Journal article The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN): PRRT in the Treatment of Neuroendocrine Tumor (NET) Patients (2021) Dureja S, Kolarova T, Mcdonnell M, Van Genechten D, Bouvier C, Gellerman E, O'Toole D, et al. Conference contribution Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability (2021) Dromain C, Sundin A, Najran P, Vidal Trueba H, Dioguardi Burgio M, Crona J, Opalinska M, et al. Journal article Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms (2021) Weindl L, Atreya I, Dietrich P, Neubeck S, Neurath M, Pavel ME Journal article